PIPELINE
Despite significant progress in cancer treatment, challenges persist, such as ensuring drugs reach tumors at effective concentrations that can be maintained over a significant period of time. We’ve reimagined cancer therapy to overcome these hurdles, providing an innovative solution to unleash the full potential of cancer-fighting drugs.
Our drug product technology platform, called Sagittari TM, has led to the development of our lead program now in clinical trials. Sagittari is being explored for its potential application across a number of indications.
| Discovery | Preclinical | IND-Enabling | Phase 1 | Phase 2 | Phase 3 | Approval | |
|---|---|---|---|---|---|---|---|
PTM-101Pancreatic Cancer |
Phase 1 |
||||||
PTM-201Undisclosed |
IND-Enabling |
PTM-101
Our lead clinical-stage program, PTM-101, is being developed for the treatment of pancreatic cancer. This program is being advanced using a well established, highly potent approved drug for treating pancreatic cancer (paclitaxel), as well as a commonly used laparoscopic procedure for implantation of PTM-101.
PTM-101 has successfully completed a small Phase I study with the following findings
- Local response demonstrated
- Excellent safety profile, well tolerated in all patients with no SAEs, no peritonitis, pancreatitis, infection, or hematologic toxicity
- No detectable level of paclitaxel systemically at any tested timepoint (<40nm/mL)
- Minimal increase in operating room time for administration of PTM-101 (<20 minutes)
See the latest clinical data for PTM-101 at AACR 2024
